Omnicell (OMCL) 10-Q 8 May 20 2020 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2020	May 01, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity File Number	000-33043
Entity Registrant Name	OMNICELL, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3166458
Entity Address, Address Line One	590 East Middlefield Road
Entity Address, City or Town	Mountain View
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94043
City Area Code	650
Local Phone Number	251-6100
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	OMCL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		42,619,693
Entity Central Index Key	0000926326
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 104,080	$ 127,210
Accounts receivable and unbilled receivables, net of allowances of $3,869 and $3,227, respectively	233,068	218,362
Inventories	112,785	108,011
Prepaid expenses	14,155	14,478
Other current assets	14,235	15,177
Total current assets	478,323	483,238
Property and equipment, net	52,997	54,246
Long-term investment in sales-type leases, net	19,992	19,750
Operating lease right-of-use assets	54,376	56,130
Goodwill	334,842	336,539
Intangible assets, net	120,063	124,867
Long-term deferred tax assets	14,142	14,142
Prepaid commissions	45,981	48,862
Other long-term assets	110,931	103,036
Total assets	1,231,647	1,240,810
Current liabilities:
Accounts payable	46,788	46,380
Accrued compensation	34,990	44,155
Accrued Liabilities, Current	58,060	55,567
Deferred revenues, net	108,602	90,894
Total current liabilities	248,440	236,996
Long-term deferred revenues	6,019	7,083
Long-term deferred tax liabilities	37,810	39,090
Long-term operating lease liabilities	48,851	50,669
Other long-term liabilities	12,027	11,718
Long-term debt	0	50,000
Total liabilities	353,147	395,556
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued	0	0
Common stock, $0.001 par value, 100,000 shares authorized; 51,751 and 51,277 shares issued; 42,606 and 42,132 shares outstanding, respectively	52	51
Treasury stock at cost, 9,145 shares outstanding, respectively	(185,074)	(185,074)
Additional paid-in capital	807,823	780,931
Retained earnings	269,839	258,792
Accumulated other comprehensive loss	(14,140)	(9,446)
Total stockholders’ equity	878,500	845,254
Total liabilities and stockholders’ equity	$ 1,231,647	$ 1,240,810

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowances for accounts receivable and unbilled receivables	$ 3,869	$ 3,227
Preferred stock, shares, issued (in shares)	0	0
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares, authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares, authorized (in shares)	100,000,000	100,000,000
Common Stock, shares, issued (in shares)	51,751,000	51,277,000
Common stock, shares, outstanding (in shares)	42,606,000	42,132,000
Treasury stock, shares (in shares)	9,145,000	9,145,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues	$ 229,686	$ 202,517
Cost of revenues	120,064	105,400
Gross profit	109,622	97,117
Operating expenses:
Research and development	18,652	16,078
Selling, general, and administrative	78,819	68,278
Total operating expenses	97,471	84,356
Income from operations	12,151	12,761
Interest and other income (expense), net	(822)	(1,410)
Income before provision for income taxes	11,329	11,351
Provision for income taxes	18	8,067
Net income	$ 11,311	$ 3,284
Net income per share:
Net income per share - basic (in dollars per share)	$ 0.27	$ 0.08
Net income per share - diluted (in dollars per share)	$ 0.26	$ 0.08
Weighted-average shares outstanding:
Weighted-average shares outstanding — basic (in shares)	42,357	40,692
Weighted-average shares outstanding — diluted (in shares)	43,621	42,281
Product revenues
Revenues	$ 170,073	$ 145,610
Cost of revenues	90,272	78,811
Services and other revenues
Revenues	59,613	56,907
Cost of revenues	$ 29,792	$ 26,589

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 11,311	$ 3,284
Other comprehensive income (loss), net of reclassification adjustments and taxes:
Unrealized losses on interest rate swap contracts	0	(317)
Foreign currency translation adjustments	(4,694)	669
Other comprehensive income (loss)	(4,694)	352
Comprehensive income	$ 6,617	$ 3,636

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Accumulated Earnings	Accumulated Other Comprehensive Income (Loss)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock, shares, outstanding (in shares)		49,480
Treasury stock, shares (in shares) at Dec. 31, 2018			(9,145)
Beginning balance at Dec. 31, 2018	$ 679,617	$ 50	$ (185,074)	$ 678,041	$ 197,454	$ (10,854)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	3,284				3,284
Other comprehensive income (loss)	352					352
At the market equity offering, net of costs (in shares)		243
At the market equity offering, net of costs	20,216			20,216
Share-based compensation	8,410			8,410
Issuance of common stock under employee stock plans (in shares)		628
Issuance of common stock under employee stock plans	20,526	$ 0		20,526
Tax payments related to restricted stock units	(1,920)			(1,920)
Treasury stock, shares (in shares) at Mar. 31, 2019			(9,145)
Ending balance at Mar. 31, 2019	$ 730,485	$ 50	$ (185,074)	725,273	200,738	(10,502)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock, shares, outstanding (in shares)		50,351
Common stock, shares, outstanding (in shares)	42,132	51,277
Treasury stock, shares (in shares) at Dec. 31, 2019	(9,145)		(9,145)
Beginning balance at Dec. 31, 2019	$ 845,254	$ 51	$ (185,074)	780,931	258,792	(9,446)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	11,311				11,311
Other comprehensive income (loss)	(4,694)					(4,694)
Share-based compensation	10,659			10,659
Issuance of common stock under employee stock plans (in shares)		474
Issuance of common stock under employee stock plans	17,659	$ 1		17,658
Tax payments related to restricted stock units	$ (1,425)			(1,425)
Treasury stock, shares (in shares) at Mar. 31, 2020	(9,145)		(9,145)
Ending balance at Mar. 31, 2020	$ 878,500	$ 52	$ (185,074)	$ 807,823	$ 269,839	$ (14,140)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock, shares, outstanding (in shares)	42,606	51,751

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating Activities
Net income	$ 11,311	$ 3,284
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	14,043	12,637
Loss on disposal of property and equipment	0	355
Share-based compensation expense	10,659	8,410
Deferred income taxes	(1,149)	3,075
Amortization of operating lease right-of-use assets	2,682	2,602
Amortization of debt issuance costs	241	573
Changes in operating assets and liabilities:
Accounts receivable and unbilled receivables	(16,052)	(7,251)
Inventories	(5,734)	(2,936)
Prepaid expenses	323	3,652
Other current assets	968	373
Investment in sales-type leases	(268)	(2,641)
Prepaid commissions	2,881	2,474
Other long-term assets	(2,844)	5,206
Accounts payable	208	(233)
Accrued compensation	(9,165)	(12,604)
Accrued liabilities	2,734	127
Deferred revenues	16,868	7,989
Operating lease liabilities	(2,784)	(2,669)
Other long-term liabilities	309	4,074
Net cash provided by operating activities	25,231	26,497
Investing Activities
Software development for external use	(10,602)	(11,717)
Purchases of property and equipment	(3,173)	(4,980)
Net cash used in investing activities	(13,775)	(16,697)
Financing Activities
Repayment of debt and revolving credit facility	(50,000)	(39,000)
At the market equity offering, net of offering costs	0	20,216
Proceeds from issuances under stock-based compensation plans	17,659	20,526
Employees’ taxes paid related to restricted stock units	(1,425)	(1,920)
Net cash used in financing activities	(33,766)	(178)
Effect of exchange rate changes on cash and cash equivalents	(820)	430
Net increase (decrease) in cash and cash equivalents	(23,130)	10,052
Cash and cash equivalents at beginning of period	127,210	67,192
Cash and cash equivalents at end of period	104,080	77,244
Supplemental disclosure of non-cash activities
Unpaid purchases of property and equipment	944	1,454
Property and equipment transferred to inventory	0	105
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 792	$ 431

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Organization and Summary of Significant Accounting Policies Business Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company’s major products are medication management automation solutions and adherence tools for healthcare systems and pharmacies, which are sold in its principal market, the healthcare industry. The Company’s market is primarily located in the United States and Europe. “Omnicell” or the “Company” collectively refer to Omnicell, Inc. and its subsidiaries. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of March 31, 2020 and December 31, 2019, the results of operations and comprehensive income for the three months ended March 31, 2020 and 2019, and cash flows for the three months ended March 31, 2020 and 2019. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company’s annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 26, 2020, except as discussed in the sections entitled “Allowance for Credit Losses” and “Recently Adopted Authoritative Guidance” below. The Company’s results of operations and comprehensive income for the three months ended March 31, 2020 and cash flows for the three months ended March 31, 2020 are not necessarily indicative of results that may be expected for the year ending December 31, 2020, or for any future period. Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Reclassifications and Adjustments Certain prior-year amounts have been reclassified to conform with current-period presentation. This reclassification was a change in the presentation of certain items in the disaggregation of product revenues for the three months ended March 31, 2019 in Note 2, Revenues , of the Notes to Condensed Consolidated Financial Statements. This change was not deemed material and was included to conform with current-period classification and presentation. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Condensed Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable, including any potential impacts arising from the novel coronavirus (“COVID-19”) pandemic. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition; accounts receivable and notes receivable from investment in sales-type leases; operating lease right-of-use assets and liabilities; inventory valuation; capitalized software development costs; impairment of goodwill and purchased intangibles; share-based compensation; and accounting for income taxes. As of March 31, 2020, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities. Given the uncertainty surrounding the COVID-19 pandemic, events or circumstances may arise that could result in a change in estimates, judgments, or revisions to the carrying value of the Company’s assets or liabilities. Segment Reporting The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment. Allowance for Credit Losses The Company is exposed to credit losses primarily through sales of its products and services, as well as its sales-type leasing arrangements. The Company performs credit evaluations of its customers’ financial condition in order to assess each customer’s ability to pay. These evaluations require significant judgment and are based on a variety of factors including, but not limited to, current economic trends, payment history, and a financial review of the customer. The Company continues to monitor customers’ creditworthiness on an ongoing basis. The Company maintains an allowance for credit losses for accounts receivable, unbilled receivables, and net investment in sales-type leases based on expected credit losses resulting from the inability of its customers to make required payments. The allowance for credit losses is measured using a loss rate method, considering factors such as customers’ credit risk, historical loss experience, current conditions, and forecasts. The allowance for credit losses is measured on a collective (pool) basis by aggregating customer balances with similar risk characteristics. The Company also records a specific allowance based on an analysis of individual past due balances or customer-specific information, such as a decline in creditworthiness or bankruptcy. Actual collection losses may differ from management’s estimates, and such differences could be material to the Company’s financial position and results of operations. The allowance for credit losses is presented in the Condensed Consolidated Balance Sheets as a deduction from the respective asset balance. The following table summarizes the Company’s allowance for credit losses by asset type: March 31, December 31, (In thousands) Allowance for credit losses: Accounts receivable and unbilled receivables $ 3,869 $ 3,227 Long-term unbilled receivables (1) 33 — Net investment in sales-type leases (2) 247 225 _________________________________________________ (1) Included in other long-term assets in the Condensed Consolidated Balance Sheets. (2) Includes both current and long-term portions presented in other current assets and long-term investment in sales-type leases, net, respectively. Changes in the allowances for credit losses were not significant for the three months ended March 31, 2020 and 2019. Recently Adopted Authoritative Guidance In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The Company adopted ASU 2018-15 on January 1, 2020 on a prospective basis. The adoption of this guidance did not have a material impact on the Company’s Condensed Consolidated Financial Statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments , that modifies or replaces existing models for trade and other receivables, debt securities, loans, and certain other financial instruments. For instruments measured at amortized cost, including trade and lease receivables, loans, and held-to-maturity debt securities, the standard replaced the current “incurred loss” approach with an “expected loss” model. Entities are required to estimate expected credit losses over the life of the instrument, considering available relevant information about the collectibility of cash flows, including information about past events, current conditions, and reasonable and supportable forecasts. The Company adopted the new standard on January 1, 2020 using the modified retrospective transition method, which resulted in the recognition of an immaterial cumulative-effect adjustment to retained earnings. Recently Issued Authoritative Guidance There was no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s Condensed Consolidated Financial Statements through the reporting date.

Revenues

Revenues	3 Months Ended
	Mar. 31, 2020
Revenue Recognition [Abstract]
Revenues	Revenues Revenue Recognition The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following performance obligations: Products. Software-enabled equipment that manages and regulates the storage and dispensing of pharmaceuticals, consumable blister cards and packaging equipment and other medical supplies. Software. Additional software applications that enable incremental functionality of the Company’s equipment or services. Installation. Installation of equipment as integrated systems at customer sites. Post-installation technical support. Phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. Professional services. Other customer services, such as training and consulting. A portion of the Company’s sales are made to customers who are members of Group Purchasing Organizations (“GPOs”). GPOs are often owned fully or in part by the Company’s customers, and the Company pays fees to the GPO on completed contracts. The Company considers these fees consideration paid to customers and records them as reductions to revenue. Fees to GPOs were $2.9 million and $2.2 million for the three months ended March 31, 2020 and 2019, respectively. Disaggregation of Revenues The following table summarizes the Company’s product revenues disaggregated by revenue type for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 (In thousands) Hardware and software $ 142,433 $ 118,814 Consumables 23,270 23,707 Other 4,370 3,089 Total product revenues $ 170,073 $ 145,610 The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 (In thousands) United States $ 207,734 $ 180,020 Rest of world (1) 21,952 22,497 Total revenues $ 229,686 $ 202,517 _________________________________________________ (1) No individual country represented more than 10% of total revenues. Contract Assets and Contract Liabilities The following table reflects the Company’s contract assets and contract liabilities: March 31, December 31, (In thousands) Short-term unbilled receivables, net (1) $ 10,048 $ 11,707 Long-term unbilled receivables, net (2) 14,338 12,260 Total contract assets $ 24,386 $ 23,967 Short-term deferred revenues, net $ 108,602 $ 90,894 Long-term deferred revenues 6,019 7,083 Total contract liabilities $ 114,621 $ 97,977 _________________________________________________ (1) Included in accounts receivable and unbilled receivables in the Condensed Consolidated Balance Sheets. (2) Included in other long-term assets in the Condensed Consolidated Balance Sheets. The portion of the transaction price allocated to the Company’s unsatisfied performance obligations for which invoicing has occurred is recorded as deferred revenues. Short-term deferred revenues of $108.6 million and $90.9 million include deferred revenues from product sales and service contracts, net of deferred cost of sales of $15.4 million and $13.1 million, as of March 31, 2020 and December 31, 2019, respectively. The short-term deferred revenues from product sales relate to delivered and invoiced products, pending installation and acceptance, expected to occur within the next twelve months. During the three months ended March 31, 2020, the Company recognized revenues of $43.4 million that were included in the corresponding gross short-term deferred revenues balance of $104.0 million as of December 31, 2019. Long-term deferred revenues include deferred revenues from service contracts of $6.0 million and $7.1 million as of March 31, 2020 and December 31, 2019, respectively. Remaining performance obligations primarily relate to maintenance contracts and are recognized ratably over the remaining term of the contract, generally not more than five years. Significant Customers There were no customers that accounted for more than 10% of the Company’s total revenues for the three months ended March 31, 2020 and 2019. Also, there were no customers that accounted for more than 10% of the Company’s accounts receivable balance as of March 31, 2020 and December 31, 2019.

Net Income Per Share

Net Income Per Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per ShareBasic net income per share is computed by dividing net income for the period by the weighted-average number of shares outstanding during the period. In periods of net loss, all potential common shares are anti-dilutive, so diluted net loss per share equals the basic net loss per share. In periods of net income, diluted net income per share is computed by dividing net income for the period by the basic weighted-average number of shares plus any dilutive potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards, and restricted stock units computed using the treasury stock method. Any anti-dilutive weighted-average dilutive shares related to stock award plans are excluded from the computation of the diluted net income per share. The basic and diluted net income per share calculations for the three months ended March 31, 2020 and 2019 were as follows: Three Months Ended March 31, 2020 2019 (In thousands, except per share data) Net income $ 11,311 $ 3,284 Weighted-average shares outstanding — basic 42,357 40,692 Effect of dilutive securities from stock award plans 1,264 1,589 Weighted-average shares outstanding — diluted 43,621 42,281 Net income per share - basic $ 0.27 $ 0.08 Net income per share - diluted $ 0.26 $ 0.08 Anti-dilutive weighted-average shares related to stock award plans 1,744 635

Cash and Cash Equivalents and F

Cash and Cash Equivalents and Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents and Fair Value of Financial Instruments	Cash and Cash Equivalents and Fair Value of Financial Instruments Cash and cash equivalents of $104.1 million and $127.2 million as of March 31, 2020 and December 31, 2019, respectively, consisted of bank accounts with major financial institutions. Fair Value Hierarchy The Company measures its financial instruments at fair value. The Company’s cash and cash equivalents are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company's interest rate swap contracts and debt are classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. Refer to Note 8, Debt and Credit Agreements, of the Notes to Condensed Consolidated Financial Statements for further information regarding the Company’s credit facilities. Interest Rate Swap Contracts The Company uses interest rate swap agreements to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company’s interest rate swaps, which are designated as cash flow hedges, involve the receipt of variable amounts from counterparties in exchange for the Company making fixed-rate payments over the life of the agreements. The Company does not hold or issue any derivative financial instruments for speculative trading purposes. During 2016, the Company entered into an interest rate swap agreement with a combined notional amount of $100.0 million with one counterparty that became effective on June 30, 2016 and matured on April 30, 2019. The swap agreement required the Company to pay a fixed rate of 0.8% and provided that the Company received a variable rate based on the one month London Interbank Offered Rate (“LIBOR”), subject to a LIBOR floor of 0.0%. Amounts payable by or due to the Company were net settled with the respective counterparty on the last business day of each month, commencing July 31, 2016.

Balance Sheet Components

Balance Sheet Components	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components Balance sheet details as of March 31, 2020 and December 31, 2019 are presented in the tables below: March 31, December 31, (In thousands) Inventories: Raw materials $ 33,945 $ 31,331 Work in process 11,957 7,620 Finished goods 66,883 69,060 Total inventories $ 112,785 $ 108,011 Other long-term assets: Capitalized software, net $ 90,395 $ 85,070 Unbilled receivables, net 14,338 12,260 Deferred debt issuance costs 4,459 4,700 Other assets 1,739 1,006 Total other long-term assets $ 110,931 $ 103,036 Accrued liabilities: Operating lease liabilities, current portion $ 9,986 $ 10,058 Advance payments from customers 6,442 4,006 Rebates and lease buyouts 15,156 14,911 Group purchasing organization fees 5,382 5,934 Taxes payable 5,974 3,744 Other accrued liabilities 15,120 16,914 Total accrued liabilities $ 58,060 $ 55,567 The following table summarizes the changes in accumulated balances of other comprehensive income (loss) for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total (In thousands) Beginning balance $ (9,446) $ — $ (9,446) $ (11,274) $ 420 $ (10,854) Other comprehensive income (loss) before reclassifications (4,694) — (4,694) 669 100 769 Amounts reclassified from other comprehensive income (loss), net of tax — — — — (417) (417) Net current-period other comprehensive income (loss), net of tax (4,694) — (4,694) 669 (317) 352 Ending balance $ (14,140) $ — $ (14,140) $ (10,605) $ 103 $ (10,502)

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment The following table represents the property and equipment balances as of March 31, 2020 and December 31, 2019: March 31, December 31, (In thousands) Equipment $ 90,128 $ 88,569 Furniture and fixtures 7,828 7,925 Leasehold improvements 19,767 18,979 Software 48,885 48,309 Construction in progress 6,106 6,179 Property and equipment, gross 172,714 169,961 Accumulated depreciation and amortization (119,717) (115,715) Total property and equipment, net $ 52,997 $ 54,246 Depreciation and amortization expense of property and equipment was $4.3 million and $4.0 million for the three months ended March 31, 2020 and 2019, respectively. The geographic location of the Company's property and equipment, net, is based on the physical location in which it is located. The following table summarizes the geographic information for property and equipment, net, as of March 31, 2020 and December 31, 2019: March 31, December 31, (In thousands) United States $ 47,955 $ 48,769 Rest of world (1) 5,042 5,477 Total property and equipment, net $ 52,997 $ 54,246 _________________________________________________ (1) No individual country represented more than 10% of total property and equipment, net.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The following table represents changes in the carrying amount of goodwill: December 31, Additions Foreign currency exchange rate fluctuations March 31, (In thousands) Goodwill $ 336,539 $ — $ (1,697) $ 334,842 Intangible Assets, Net The carrying amounts and useful lives of intangible assets as of March 31, 2020 and December 31, 2019 were as follows: March 31, 2020 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 134,889 $ (56,727) $ (1,398) $ 76,764 10 - 30 Acquired technology 77,029 (38,058) 4 38,975 5 - 20 Backlog 1,150 (863) — 287 4 Trade names 7,650 (5,206) 9 2,453 6 - 12 Patents 3,217 (1,633) — 1,584 2 - 20 Total intangibles assets, net $ 223,935 $ (102,487) $ (1,385) $ 120,063 December 31, 2019 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 135,234 $ (54,860) $ (1,058) $ 79,316 10 - 30 Acquired technology 77,142 (36,194) 5 40,953 3 - 20 Backlog 1,150 (791) — 359 4 Trade names 7,650 (5,037) 11 2,624 6 - 12 Patents 3,217 (1,603) 1 1,615 2 - 20 Total intangibles assets, net $ 224,393 $ (98,485) $ (1,041) $ 124,867 _________________________________________________ (1) The differences in gross carrying amounts between periods are primarily due to the write-off of certain fully amortized intangible assets. Amortization expense of intangible assets was $4.5 million and $4.8 million for the three months ended March 31, 2020 and 2019, respectively. The estimated future amortization expenses for amortizable intangible assets were as follows: March 31, (In thousands) Remaining nine months of 2020 $ 12,987 2021 16,123 2022 14,775 2023 13,679 2024 7,920 Thereafter 54,579 Total $ 120,063

Debt and Credit Agreements

Debt and Credit Agreements	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Debt and Credit Agreements	Debt and Credit Agreements 2016 Senior Credit Facility On January 5, 2016, the Company entered into a $400.0 million senior secured credit facility pursuant to a credit agreement with certain lenders, Wells Fargo Securities, LLC as sole lead arranger, and Wells Fargo Bank, National Association as administrative agent (as subsequently amended as discussed below, the “Prior Credit Agreement”). The Prior Credit Agreement provided for (a) a five five Loans under the Prior Facilities bore interest, at the Company’s option, at a rate equal to either (a) LIBOR, plus an applicable margin ranging from 1.50% to 2.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Prior Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) LIBOR for an interest period of one month, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Prior Credit Agreement). Undrawn commitments under the Prior Revolving Credit Facility were subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Prior Revolving Credit Facility. On each of April 11, 2017 and December 26, 2017, the parties entered into amendments to the Prior Credit Agreement. Under these amendments, the Prior Revolving Credit Facility was increased from $200.0 million to $315.0 million, and certain other modifications were made. In connection with the December 2017 amendment, the Company incurred and capitalized an additional $2.1 million of debt issuance costs. 2019 Revolving Credit Facility On November 15, 2019, the Company refinanced the Prior Credit Agreement and entered into an Amended and Restated Credit Agreement (the “A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers and Wells Fargo Bank, National Association, as administrative agent. The A&R Credit Agreement replaced the Prior Credit Agreement and provides for (a) a five On November 15, 2019, the $80.0 million outstanding term loan balance under the Prior Facilities was transferred to the Current Revolving Credit Facility. Loans under the Current Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) LIBOR, plus an applicable margin ranging from 1.25% to 2.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) LIBOR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.25% to 1.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Current Revolving Credit Facility are subject to a commitment fee ranging from 0.15% to 0.30% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Current Revolving Credit Facility. The applicable margin for and certain other terms of any term loans under the Incremental Facility will be determined prior to the incurrence of such loans. The Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty. The A&R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The A&R Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum consolidated total net leverage ratio and maintain a minimum interest coverage ratio. In addition, the A&R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal and fees or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults and events of bankruptcy. The Company’s obligations under the A&R Credit Agreement and any swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the A&R Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement. The Company was in full compliance with all covenants as of March 31, 2020. The refinancing of the Prior Credit Agreement was evaluated in accordance with Accounting Standards Codification (“ASC”) 470-50, Debt - Modifications and Extinguishments . In determining whether the refinancing was to be accounted for as a debt extinguishment or a debt modification, the Company considered whether lenders within the syndicate remained the same or changed and whether the changes in debt terms were substantial. This assessment was performed on an individual lender basis within the syndicate. As a result, the refinancing was accounted for as a modification with the exception of certain lenders that exited the syndicate. The exit of certain lenders resulted in an immaterial write-off of existing unamortized debt issuance costs. The remaining unamortized debt issuance costs related to debt modification, along with the new deferred costs, will be amortized over the remaining term of the A&R Credit Agreement. In connection with the A&R Credit Agreement, the Company incurred and capitalized an additional $2.3 million of debt issuance costs. The debt issuance costs are being amortized to interest expense using the straight-line method through 2024. Amortization expense related to debt issuance costs was approximately $0.2 million and $0.6 million for the three months ended March 31, 2020 and 2019, respectively. Interest expense (exclusive of fees and debt issuance cost amortization) was approximately $0.2 million and $1.3 million for the three months ended March 31, 2020 and 2019, respectively. The following table represents changes in the carrying amount of the Company’s debt obligations: Current Revolving Credit Facility (In thousands) Balance as of December 31, 2019 $ 50,000 Proceeds — Repayments (50,000) Balance as of March 31, 2020 $ — The following table represents changes in the balance of the Company's deferred debt issuance costs: (In thousands) Balance as of December 31, 2019 $ 4,700 Additions — Amortization (241) Balance as of March 31, 2020 $ 4,459

Lessor Leases

Lessor Leases	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Lessor Leases	Lessor Leases Sales-Type Leases On a recurring basis, the Company enters into multi-year, sales-type lease agreements, with the majority varying in length from one The following table presents the Company’s income recognized from sales-type leases for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 (In thousands) Sales-type lease revenues $ 6,392 $ 11,507 Cost of sales-type lease revenues (2,569) (4,820) Selling profit on sales-type lease revenues $ 3,823 $ 6,687 Interest income on sales-type lease receivables $ 461 $ 409 The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at March 31, 2020 and December 31, 2019: March 31, December 31, (In thousands) Net minimum lease payments to be received $ 32,681 $ 32,360 Less: Unearned interest income portion (2,893) (2,840) Net investment in sales-type leases 29,788 29,520 Less: Current portion (1) (9,796) (9,770) Long-term investment in sales-type leases, net $ 19,992 $ 19,750 _________________________________________________ (1) The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets. The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value. The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows: March 31, (In thousands) Remaining nine months of 2020 $ 8,838 2021 8,048 2022 7,283 2023 5,110 2024 2,393 Thereafter 1,009 Total future minimum sales-type lease payments 32,681 Present value adjustment (2,893) Total net investment in sales-type leases $ 29,788 Operating Leases The Company entered into certain leasing agreements that were classified as operating leases prior to the adoption of ASC 842, Leases , on January 1, 2019. These agreements in place prior to January 1, 2019 will continue to be treated as operating leases, however any new leasing agreements entered into on or after January 1, 2019 under these programs are classified and accounted for as sales-type leases in accordance with ASC 842. The operating lease arrangements generally have initial terms of one The following table represents the Company’s income recognized from operating leases for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 (In thousands) Rental income $ 2,977 $ 3,287
Lessor Leases	Lessor Leases Sales-Type Leases On a recurring basis, the Company enters into multi-year, sales-type lease agreements, with the majority varying in length from one The following table presents the Company’s income recognized from sales-type leases for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 (In thousands) Sales-type lease revenues $ 6,392 $ 11,507 Cost of sales-type lease revenues (2,569) (4,820) Selling profit on sales-type lease revenues $ 3,823 $ 6,687 Interest income on sales-type lease receivables $ 461 $ 409 The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at March 31, 2020 and December 31, 2019: March 31, December 31, (In thousands) Net minimum lease payments to be received $ 32,681 $ 32,360 Less: Unearned interest income portion (2,893) (2,840) Net investment in sales-type leases 29,788 29,520 Less: Current portion (1) (9,796) (9,770) Long-term investment in sales-type leases, net $ 19,992 $ 19,750 _________________________________________________ (1) The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets. The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value. The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows: March 31, (In thousands) Remaining nine months of 2020 $ 8,838 2021 8,048 2022 7,283 2023 5,110 2024 2,393 Thereafter 1,009 Total future minimum sales-type lease payments 32,681 Present value adjustment (2,893) Total net investment in sales-type leases $ 29,788 Operating Leases The Company entered into certain leasing agreements that were classified as operating leases prior to the adoption of ASC 842, Leases , on January 1, 2019. These agreements in place prior to January 1, 2019 will continue to be treated as operating leases, however any new leasing agreements entered into on or after January 1, 2019 under these programs are classified and accounted for as sales-type leases in accordance with ASC 842. The operating lease arrangements generally have initial terms of one The following table represents the Company’s income recognized from operating leases for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 (In thousands) Rental income $ 2,977 $ 3,287

Lessee Leases

Lessee Leases	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Lessee Leases	Lessee Leases The Company has operating leases for office buildings, data centers, office equipment, and vehicles. The Company’s leases have initial terms of one The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Condensed Consolidated Balance Sheets was as follows: March 31, (In thousands) Remaining nine months of 2020 $ 10,076 2021 13,274 2022 12,157 2023 8,595 2024 8,014 Thereafter 20,100 Total operating lease payments 72,216 Present value adjustment (13,379) Total operating lease liabilities (1) $ 58,837 _________________________________________________ (1) Amount consists of a current and long-term portion of operating lease liabilities of $10.0 million and $48.9 million, respectively. The short-term portion of the operating lease liabilities is included in accrued liabilities in the Condensed Consolidated Balance Sheets. Operating lease costs were $3.6 million and $3.7 million for the three months ended March 31, 2020 and 2019, respectively. Short-term lease costs and variable lease costs were immaterial for the three months ended March 31, 2020 and 2019. The following table summarizes supplemental cash flow information related to the Company’s operating leases for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 (In thousands) Cash paid for amounts included in the measurement of lease liabilities $ 3,735 $ 3,761 Right-of-use assets obtained in exchange for new lease liabilities $ 792 $ 431 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of March 31, 2020 and 2019: March 31, December 31, Weighted-average remaining lease term, years 6.3 6.4 Weighted-average discount rate, % 6.4 % 6.4 %

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Obligations In the ordinary course of business, the Company issues purchase orders based on its current manufacturing needs. As of March 31, 2020, the Company had non-cancelable purchase commitments of $91.7 million, of which $90.2 million are expected to be paid within the year ending December 31, 2020. Legal Proceedings The Company is currently involved in various legal proceedings. As required under ASC 450, Contingencies , the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any accrual for contingent liabilities associated with the legal proceedings described below based on its belief that any potential loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time. The Company believes that it has valid defenses with respect to legal proceedings pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of this contingency or because of the diversion of management’s attention and the creation of significant expenses. On January 10, 2018, a lawsuit was filed against a number of individuals, governmental agencies, and corporate entities, including the Company and one of its former subsidiaries, Aesynt Incorporated (“Aesynt”), which, through a series of mergers, has been merged into the Company, in the Circuit Court for the City of Richmond, Virginia, captioned Ruth Ann Warner, as Guardian of Jonathan James Brewster Warner v. Centra Health, Inc., et al., Case No. CL18-152-1 . The complaint sought monetary recovery of compensatory and punitive damages in addition to certain declaratory relief based upon, as against the individuals, governmental agencies, and corporate entities other than the Company and Aesynt, allegations of the use of excessive force, unlawful detention, false imprisonment, battery, simple and gross negligence and negligent hiring, detention, and training; and, as against the Company and Aesynt, claims of product liability, negligence, and breach of implied warranties. The Company and Aesynt were never served with the complaint. Upon motion of the plaintiff, the Court issued an order on February 21, 2019 nonsuiting (dismissing) the case without prejudice. On August 21, 2019, a new lawsuit was filed against the Company and Aesynt, in the Circuit Court for the County of Albemarle, Virginia, captioned Ruth Ann Warner, as Guardian of Jonathan James Brewster Warner v. Aesynt Incorporated, et al., Case No CL19-1301 . The complaint seeks monetary recovery of damages based upon claims of product liability, negligence, and breach of implied warranties. The Company and Aesynt have not been served with the complaint. The Company intends to defend the lawsuit vigorously. A declaratory judgment action was filed against the Company, on August 30, 2018, in the United States District Court for the Northern District of California, captioned Zurich American Insurance Company; American Guarantee & Liability Company v. Omnicell, Inc. and Does 1-10, inclusive, Case No. 3:18-CV-05345 . The complaint seeks a declaration that the plaintiffs have no duty to defend or indemnify the Company in connection with the underlying litigation, Yana Mazya, et al. v. Northwestern Lake Forest Hospital, et al., Case No. 2018-CH-07161 pending in the Circuit Court of Cook County, Illinois, Chancery Division (a class action lawsuit filed against a customer of the Company, the customer’s parent company, and two vendors of medication dispensing systems, one of which is the Company, seeking statutory damages and certain declaratory, injunctive, and other relief based on causes of action directed to allegations of violation of the Illinois Biometric Information Privacy Act (“BIPA”) and of negligence by the defendants from which the Company was subsequently dismissed without prejudice) (“Mazya Action”), together with claims for reimbursement and unjust enrichment relating to the defense of the Mazya Action in the form of attorneys’ fees and other related costs. The Company has not responded to the complaint. On February 12, 2019, the Court stayed the action pending the outcome of the Mazya Action and administratively closed the case. On October 15, 2019, the plaintiffs filed a notice advising the Court of the dismissal of the Company from the Mazya Action and requesting that the Court lift the stay in the case and set dates for filing a responsive pleading by the Company and initial discovery and scheduling matters. By order dated November 13, 2019, the Court (i) lifted the stay in the case, (ii) set a case management conference for February 5, 2020, and (iii) ordered the parties to file a joint case management statement by January 29, 2020. The parties subsequently reached a settlement of the case in principle and the Court, after notice of the parties, continued the case management conference until April 29, 2020. The parties entered into a written settlement agreement on April 9, 2020. Since the conditions precedent in the settlement agreement to dismissing the case had not yet been fulfilled, the Court, upon the petition of the parties, again continued the case management conference until May 27, 2020. Upon fulfillment of the conditions precedent to finalizing the settlement, the plaintiffs filed a notice of dismissal with prejudice on May 4, 2020, thereby finally terminating the action. A class action lawsuit was filed against the Company, on June 5, 2019, in the Circuit Court of Cook County, Illinois, Chancery Division, captioned Corey Heard, individually and on behalf of all others similarly situated, v. Omnicell, Inc., Case No. 2019-CH-06817 . The complaint seeks class certification, monetary damages in the form of statutory damages for willful and/or reckless or, in the alternative, negligent violation of BIPA, and certain declaratory, injunctive, and other relief based on causes of action directed to allegations of violation of BIPA by the Company. The complaint was served on the Company on June 13, 2019. On July 31, 2019, the Company filed a motion to stay or consolidate the case with the Mazya Action. The Court subsequently, on October 10, 2019, denied the motion, without prejudice, as being moot in view of the Company’s dismissal from the Mazya Action. The Company filed a motion to dismiss the complaint on October 31, 2019. The motion to dismiss is fully-briefed. The hearing on the Company’s motion to dismiss was previously set for March 16, 2020, but has been continued to May 27, 2020. The Company intends to defend the lawsuit vigorously. In August 2019, the Company received a letter from the Denver office of the SEC seeking information related to the Company’s accounting processes and procedures. The Company responded and fully cooperated with the SEC. On February 12, 2020, the Company received a letter from the SEC confirming that it has concluded its investigation and that the SEC does not intend to recommend any enforcement action against the Company.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company generally provides for income taxes in interim periods based on the estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. The annual effective tax rate before discrete items was 26.6% and 23.3% for the three months ended March 31, 2020 and 2019, respectively. The Company’s effective tax rate for the three months ended March 31, 2020 was based on best estimates, which may fluctuate through the remainder of the year due to the volatility and uncertainty of global economic conditions in connection with the COVID-19 pandemic. Due to continuing global operational centralization activities and legal entity rationalization, the Company recognized gain on the sale of certain intellectual property rights by Aesynt B.V. to Omnicell, Inc., which resulted in a tax expense, net of tax benefit, of $9.6 million during the three months ended March 31, 2019. The Company did not recognize a gain or loss from such activities during the three months ended March 31, 2020. The Company also recognized a discrete tax benefit related to equity compensation in the amount of $2.8 million and $4.6 million for the three months ended March 31, 2020 and 2019, respectively. The 2020 annual effective tax rate differed from the statutory rate of 21% primarily due to the unfavorable impact of state income taxes, non-deductible compensation and equity charges, and non-deductible expenses, partially offset by the favorable impact of research and development credits and foreign derived intangible income (“FDII”) benefit deduction. The 2019 annual effective tax rate differed from the statutory rate of 21% primarily due to the unfavorable impact of state income taxes, non-deductible equity charges, and non-deductible expenses, partially offset by the favorable impact of research and development credits, foreign rate differential, and FDII benefit deduction. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) was signed into law in response to the COVID-19 pandemic. The CARES Act, among other provisions, includes provisions related to refundable payroll tax credits, deferment of the employer portion of certain payroll taxes, net operation losses carryback periods, alternative minimum tax credit refunds, modification to net interest expense deduction limitation, and technical amendments to tax depreciation methods for qualified improvement property placed in service after December 31, 2017. The Company does not expect these provisions of the CARES Act to have a material impact on income taxes. As of March 31, 2020 and December 31, 2019, the Company had gross unrecognized tax benefits of $17.0 million and $16.8 million, respectively. It is the Company’s policy to classify accrued interest and penalties as part of the unrecognized tax benefits, but to record interest and penalties in interest and other income (expense), net in the Condensed Consolidated Statements of Operations. As of March 31, 2020 and December 31, 2019, the amount of accrued interest and penalties was $1.1 million and $1.0 million, respectively. The Company files income tax returns in the United States and various states and foreign jurisdictions. In the normal course of business, the Company is subject to examination by taxing authorities, including major jurisdictions such as the United States, Germany, Italy, Netherlands, and the United Kingdom. With few exceptions, as of March 31, 2020, the Company was no longer subject to United States, state, and foreign examination for years before 2016, 2015, and 2015, respectively. Although the Company believes it has adequately provided for uncertain tax positions, the provisions on these positions may change as revised estimates are made or the underlying matters are settled or otherwise resolved. It is not possible at this time to reasonably estimate changes in the unrecognized tax benefits within the next twelve months.

Employee Benefits and Share-Bas

Employee Benefits and Share-Based Compensation	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Employee Benefits and Share-Based Compensation	Employee Benefits and Share-Based Compensation Stock-Based Plans For a detailed explanation of the Company's stock plans, refer to Note 13, Employee Benefits and Share-Based Compensation , of the Company's annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 26, 2020. Share-Based Compensation Expense The following table sets forth the total share-based compensation expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 (In thousands) Cost of product and service revenues $ 1,770 $ 1,462 Research and development 1,768 1,702 Selling, general, and administrative 7,121 5,246 Total share-based compensation expense $ 10,659 $ 8,410 Stock Options and ESPP Shares The following assumptions were used to value stock options and Employee Stock Purchase Plan (“ESPP”) shares granted pursuant to the Company’s equity incentive plans for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 Stock options Expected life, years 4.7 4.5 Expected volatility, % 33.6 % 33.1 % Risk-free interest rate, % 1.4 % 2.6 % Estimated forfeiture rate, % 5.7 % 7.2 % Dividend yield, % — % — % Three Months Ended March 31, 2020 2019 Employee stock purchase plan shares Expected life, years 0.5 - 2.0 0.5 - 2.0 Expected volatility, % 30.4% - 39.9% 28.2% - 38.4% Risk-free interest rate, % 1.4% - 2.7% 1.3% - 2.7% Dividend yield, % — % — % Stock Options Activity The following table summarizes the share option activity under the Company’s equity incentive plans during the three months ended March 31, 2020: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2019 3,902 $ 52.75 7.7 $ 113,198 Granted 430 85.32 Exercised (227) 36.20 Expired (2) 51.50 Forfeited (65) 64.06 Outstanding at March 31, 2020 4,038 $ 56.96 7.8 $ 57,180 Exercisable at March 31, 2020 1,586 $ 39.38 6.3 $ 42,826 Vested and expected to vest at March 31, 2020 and thereafter 3,846 $ 56.18 7.7 $ 56,526 The weighted-average fair value per share of options granted during the three months ended March 31, 2020 and 2019 was $26.31 and $24.07, respectively. The intrinsic value of options exercised during the three months ended March 31, 2020 and 2019 was $9.9 million and $17.1 million, respectively. As of March 31, 2020, total unrecognized compensation cost related to unvested stock options was $46.6 million, which is expected to be recognized over a weighted-average vesting period of 2.9 years. Employee Stock Purchase Plan Activity For the three months ended March 31, 2020 and 2019, employees purchased approximately 217,000 and 210,000 shares of common stock, respectively, under the ESPP at weighted average prices of $43.51 and $40.20, respectively. As of March 31, 2020, the unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $7.7 million and is expected to be recognized over a weighted-average period of 1.4 years. Restricted Stock Units (“RSUs”) and Restricted Stock Awards (“RSAs”) Summaries of the restricted stock activity under the Company’s 2009 Equity Incentive Plan, as amended (the “2009 Plan”) are presented below for the three months ended March 31, 2020: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Restricted stock units Outstanding at December 31, 2019 544 $ 66.65 1.6 $ 44,492 Granted (Awarded) 62 85.05 Vested (Released) (33) 54.41 Forfeited (17) 66.06 Outstanding and unvested at March 31, 2020 556 $ 69.44 1.6 $ 36,482 As of March 31, 2020, total unrecognized compensation cost related to RSUs was $34.1 million, which is expected to be recognized over the remaining weighted-average vesting period of 3.0 years. Number of Weighted-Average (In thousands, except per share data) Restricted stock awards Outstanding at December 31, 2019 17 $ 81.92 Granted (Awarded) — — Vested (Released) — — Outstanding and unvested at March 31, 2020 17 $ 81.92 As of March 31, 2020, total unrecognized compensation cost related to RSAs was $0.2 million, which is expected to be recognized over the remaining weighted-average vesting period of 0.1 years. Performance-Based Restricted Stock Units (“PSUs”) A summary of the performance-based restricted stock activity under the 2009 Plan is presented below for the three months ended March 31, 2020: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2019 134 $ 55.82 Granted 63 82.41 Vested (15) 72.02 Forfeited — — Outstanding and unvested at March 31, 2020 182 $ 63.63 As of March 31, 2020, total unrecognized compensation cost related to PSUs was approximately $6.7 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.5 years. Summary of Shares Reserved for Future Issuance under Equity Incentive Plans The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of March 31, 2020: Number of Shares (In thousands) Share options outstanding 4,038 Non-vested restricted stock awards 755 Shares authorized for future issuance 2,252 ESPP shares available for future issuance 1,322 Total shares reserved for future issuance 8,367 Stock Repurchase Program On August 2, 2016, the Company's Board of Directors (the “Board”) authorized a stock repurchase program providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). The 2016 Repurchase Program is in addition to the stock repurchase program approved by the Board on November 4, 2014. As of March 31, 2020, the maximum dollar value of shares that may yet be purchased under the two repurchase programs was $54.9 million. The stock repurchase programs do not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the repurchase programs at any time.

Equity Offerings

Equity Offerings	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Equity Offerings	Equity Offerings On November 3, 2017, the Company entered into a Distribution Agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC, Wells Fargo Securities, LLC, and HSBC Securities (USA) Inc., as its sales agents, pursuant to which the Company may offer and sell from time to time through the sales agents up to $125.0 million maximum aggregate offering price of the Company’s common stock. Sales of the common stock pursuant to the Distribution Agreement may be made in negotiated transactions or transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, including sales made directly on the Nasdaq Stock Market, or sales made to or through a market maker other than on an exchange. For the three months ended March 31, 2020, the Company did not sell any of its common stock under the Distribution Agreement. For the three months ended March 31, 2019, the Company received gross proceeds of $20.6 million from sales of its common stock under the Distribution Agreement and incurred issuance costs of $0.4 million on sales of approximately 243,000 shares of its common stock at an average price of approximately $84.98 per share.

Restructuring Expenses

Restructuring Expenses	3 Months Ended
	Mar. 31, 2020
Restructuring and Related Activities [Abstract]
Restructuring Expenses	Restructuring ExpensesIn the first quarter of 2020, the Company announced a company-wide organizational realignment initiative in order to more effectively align its organizational infrastructure and operations with the strategic vision of the autonomous pharmacy. During the three months ended March 31, 2020, the Company incurred and accrued $3.5 million of employee severance costs and related expenses. As of March 31, 2020, the unpaid balance related to this restructuring plan was $1.7 million.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies - (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of March 31, 2020 and December 31, 2019, the results of operations and comprehensive income for the three months ended March 31, 2020 and 2019, and cash flows for the three months ended March 31, 2020 and 2019. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company’s annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 26, 2020, except as discussed in the sections entitled “Allowance for Credit Losses” and “Recently Adopted Authoritative Guidance” below. The Company’s results of operations and comprehensive income for the three months ended March 31, 2020 and cash flows for the three months ended March 31, 2020 are not necessarily indicative of results that may be expected for the year ending December 31, 2020, or for any future period.
Principles of Consolidation	Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Reclassifications and Adjustments	Reclassifications and AdjustmentsCertain prior-year amounts have been reclassified to conform with current-period presentation.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Condensed Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable, including any potential impacts arising from the novel coronavirus (“COVID-19”) pandemic. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates.
Segment Reporting	Segment Reporting The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM
Allowance for Credit Losses	Allowance for Credit Losses The Company is exposed to credit losses primarily through sales of its products and services, as well as its sales-type leasing arrangements. The Company performs credit evaluations of its customers’ financial condition in order to assess each customer’s ability to pay. These evaluations require significant judgment and are based on a variety of factors including, but not limited to, current economic trends, payment history, and a financial review of the customer. The Company continues to monitor customers’ creditworthiness on an ongoing basis. The Company maintains an allowance for credit losses for accounts receivable, unbilled receivables, and net investment in sales-type leases based on expected credit losses resulting from the inability of its customers to make required payments. The allowance for credit losses is measured using a loss rate method, considering factors such as customers’ credit risk, historical loss experience, current conditions, and forecasts. The allowance for credit losses is measured on a collective (pool) basis by aggregating customer balances with similar risk characteristics. The Company also records a specific allowance based on an analysis of individual past due balances or customer-specific information, such as a decline in creditworthiness or bankruptcy. Actual collection losses may differ from management’s estimates, and such differences could be material to the Company’s financial position and results of operations.
Recently Adopted and Issued Authoritative Guidance	Recently Adopted Authoritative Guidance In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The Company adopted ASU 2018-15 on January 1, 2020 on a prospective basis. The adoption of this guidance did not have a material impact on the Company’s Condensed Consolidated Financial Statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments , that modifies or replaces existing models for trade and other receivables, debt securities, loans, and certain other financial instruments. For instruments measured at amortized cost, including trade and lease receivables, loans, and held-to-maturity debt securities, the standard replaced the current “incurred loss” approach with an “expected loss” model. Entities are required to estimate expected credit losses over the life of the instrument, considering available relevant information about the collectibility of cash flows, including information about past events, current conditions, and reasonable and supportable forecasts. The Company adopted the new standard on January 1, 2020 using the modified retrospective transition method, which resulted in the recognition of an immaterial cumulative-effect adjustment to retained earnings. Recently Issued Authoritative Guidance There was no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s Condensed Consolidated Financial Statements through the reporting date.
Revenue Recognition	Revenue Recognition The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following performance obligations: Products. Software-enabled equipment that manages and regulates the storage and dispensing of pharmaceuticals, consumable blister cards and packaging equipment and other medical supplies. Software. Additional software applications that enable incremental functionality of the Company’s equipment or services. Installation. Installation of equipment as integrated systems at customer sites. Post-installation technical support. Phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. Professional services. Other customer services, such as training and consulting.

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies - (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Allowance for Credit Losses by Asset Type	The following table summarizes the Company’s allowance for credit losses by asset type: March 31, December 31, (In thousands) Allowance for credit losses: Accounts receivable and unbilled receivables $ 3,869 $ 3,227 Long-term unbilled receivables (1) 33 — Net investment in sales-type leases (2) 247 225 _________________________________________________ (1) Included in other long-term assets in the Condensed Consolidated Balance Sheets.

Revenues - (Tables)

Revenues - (Tables)	3 Months Ended
	Mar. 31, 2020
Revenue Recognition [Abstract]
Disaggregation of Revenues by Revenue Type	The following table summarizes the Company’s product revenues disaggregated by revenue type for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 (In thousands) Hardware and software $ 142,433 $ 118,814 Consumables 23,270 23,707 Other 4,370 3,089 Total product revenues $ 170,073 $ 145,610
Disaggregation of Revenues by Geographical Location	The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 (In thousands) United States $ 207,734 $ 180,020 Rest of world (1) 21,952 22,497 Total revenues $ 229,686 $ 202,517 _________________________________________________ (1) No individual country represented more than 10% of total revenues.
Contract Asset and Liabilities	The following table reflects the Company’s contract assets and contract liabilities: March 31, December 31, (In thousands) Short-term unbilled receivables, net (1) $ 10,048 $ 11,707 Long-term unbilled receivables, net (2) 14,338 12,260 Total contract assets $ 24,386 $ 23,967 Short-term deferred revenues, net $ 108,602 $ 90,894 Long-term deferred revenues 6,019 7,083 Total contract liabilities $ 114,621 $ 97,977 _________________________________________________ (1) Included in accounts receivable and unbilled receivables in the Condensed Consolidated Balance Sheets.

Net Income Per Share - (Tables)

Net Income Per Share - (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Basic and Diluted Net Income Per Share	The basic and diluted net income per share calculations for the three months ended March 31, 2020 and 2019 were as follows: Three Months Ended March 31, 2020 2019 (In thousands, except per share data) Net income $ 11,311 $ 3,284 Weighted-average shares outstanding — basic 42,357 40,692 Effect of dilutive securities from stock award plans 1,264 1,589 Weighted-average shares outstanding — diluted 43,621 42,281 Net income per share - basic $ 0.27 $ 0.08 Net income per share - diluted $ 0.26 $ 0.08 Anti-dilutive weighted-average shares related to stock award plans 1,744 635

Balance Sheet Components - (Tab

Balance Sheet Components - (Tables)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance sheet details as of March 31, 2020 and December 31, 2019 are presented in the tables below: March 31, December 31, (In thousands) Inventories: Raw materials $ 33,945 $ 31,331 Work in process 11,957 7,620 Finished goods 66,883 69,060 Total inventories $ 112,785 $ 108,011 Other long-term assets: Capitalized software, net $ 90,395 $ 85,070 Unbilled receivables, net 14,338 12,260 Deferred debt issuance costs 4,459 4,700 Other assets 1,739 1,006 Total other long-term assets $ 110,931 $ 103,036 Accrued liabilities: Operating lease liabilities, current portion $ 9,986 $ 10,058 Advance payments from customers 6,442 4,006 Rebates and lease buyouts 15,156 14,911 Group purchasing organization fees 5,382 5,934 Taxes payable 5,974 3,744 Other accrued liabilities 15,120 16,914 Total accrued liabilities $ 58,060 $ 55,567
Schedule of Accumulated Other Comprehensive Income (Loss)	The following table summarizes the changes in accumulated balances of other comprehensive income (loss) for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total (In thousands) Beginning balance $ (9,446) $ — $ (9,446) $ (11,274) $ 420 $ (10,854) Other comprehensive income (loss) before reclassifications (4,694) — (4,694) 669 100 769 Amounts reclassified from other comprehensive income (loss), net of tax — — — — (417) (417) Net current-period other comprehensive income (loss), net of tax (4,694) — (4,694) 669 (317) 352 Ending balance $ (14,140) $ — $ (14,140) $ (10,605) $ 103 $ (10,502)

Property and Equipment - (Table

Property and Equipment - (Tables)	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Balances	The following table represents the property and equipment balances as of March 31, 2020 and December 31, 2019: March 31, December 31, (In thousands) Equipment $ 90,128 $ 88,569 Furniture and fixtures 7,828 7,925 Leasehold improvements 19,767 18,979 Software 48,885 48,309 Construction in progress 6,106 6,179 Property and equipment, gross 172,714 169,961 Accumulated depreciation and amortization (119,717) (115,715) Total property and equipment, net $ 52,997 $ 54,246
Summary of the Geographic Information for Property and Equipment, Net	The following table summarizes the geographic information for property and equipment, net, as of March 31, 2020 and December 31, 2019: March 31, December 31, (In thousands) United States $ 47,955 $ 48,769 Rest of world (1) 5,042 5,477 Total property and equipment, net $ 52,997 $ 54,246 _________________________________________________ (1) No individual country represented more than 10% of total property and equipment, net.

Goodwill and Intangible Assets

Goodwill and Intangible Assets - (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The following table represents changes in the carrying amount of goodwill: December 31, Additions Foreign currency exchange rate fluctuations March 31, (In thousands) Goodwill $ 336,539 $ — $ (1,697) $ 334,842
Carrying Amounts and Useful Lives of Intangible Assets	The carrying amounts and useful lives of intangible assets as of March 31, 2020 and December 31, 2019 were as follows: March 31, 2020 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 134,889 $ (56,727) $ (1,398) $ 76,764 10 - 30 Acquired technology 77,029 (38,058) 4 38,975 5 - 20 Backlog 1,150 (863) — 287 4 Trade names 7,650 (5,206) 9 2,453 6 - 12 Patents 3,217 (1,633) — 1,584 2 - 20 Total intangibles assets, net $ 223,935 $ (102,487) $ (1,385) $ 120,063 December 31, 2019 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 135,234 $ (54,860) $ (1,058) $ 79,316 10 - 30 Acquired technology 77,142 (36,194) 5 40,953 3 - 20 Backlog 1,150 (791) — 359 4 Trade names 7,650 (5,037) 11 2,624 6 - 12 Patents 3,217 (1,603) 1 1,615 2 - 20 Total intangibles assets, net $ 224,393 $ (98,485) $ (1,041) $ 124,867 _________________________________________________
Estimated Future Amortization Expense for Intangible Assets	The estimated future amortization expenses for amortizable intangible assets were as follows: March 31, (In thousands) Remaining nine months of 2020 $ 12,987 2021 16,123 2022 14,775 2023 13,679 2024 7,920 Thereafter 54,579 Total $ 120,063

Debt and Credit Agreement (Tabl

Debt and Credit Agreement (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Changes in the Carrying Amount of Debt Obligations	The following table represents changes in the carrying amount of the Company’s debt obligations: Current Revolving Credit Facility (In thousands) Balance as of December 31, 2019 $ 50,000 Proceeds — Repayments (50,000) Balance as of March 31, 2020 $ —
Changes in the Balance of Deferred Debt Issuance Costs	The following table represents changes in the balance of the Company's deferred debt issuance costs: (In thousands) Balance as of December 31, 2019 $ 4,700 Additions — Amortization (241) Balance as of March 31, 2020 $ 4,459

Lessor Leases (Tables)

Lessor Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Income Recognized from Sales-Type Leases	The following table presents the Company’s income recognized from sales-type leases for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 (In thousands) Sales-type lease revenues $ 6,392 $ 11,507 Cost of sales-type lease revenues (2,569) (4,820) Selling profit on sales-type lease revenues $ 3,823 $ 6,687 Interest income on sales-type lease receivables $ 461 $ 409
Components of Sales-Type Lease Receivables	The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at March 31, 2020 and December 31, 2019: March 31, December 31, (In thousands) Net minimum lease payments to be received $ 32,681 $ 32,360 Less: Unearned interest income portion (2,893) (2,840) Net investment in sales-type leases 29,788 29,520 Less: Current portion (1) (9,796) (9,770) Long-term investment in sales-type leases, net $ 19,992 $ 19,750 _________________________________________________ (1) The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets.
Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases	The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows: March 31, (In thousands) Remaining nine months of 2020 $ 8,838 2021 8,048 2022 7,283 2023 5,110 2024 2,393 Thereafter 1,009 Total future minimum sales-type lease payments 32,681 Present value adjustment (2,893) Total net investment in sales-type leases $ 29,788
Income Recognized from Operating Leases	The following table represents the Company’s income recognized from operating leases for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 (In thousands) Rental income $ 2,977 $ 3,287

Lessee Leases (Tables)

Lessee Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities	The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Condensed Consolidated Balance Sheets was as follows: March 31, (In thousands) Remaining nine months of 2020 $ 10,076 2021 13,274 2022 12,157 2023 8,595 2024 8,014 Thereafter 20,100 Total operating lease payments 72,216 Present value adjustment (13,379) Total operating lease liabilities (1) $ 58,837 _________________________________________________ (1) Amount consists of a current and long-term portion of operating lease liabilities of $10.0 million and $48.9 million, respectively. The short-term portion of the operating lease liabilities is included in accrued liabilities in the Condensed Consolidated Balance Sheets.
Supplemental Cash Flow Information Related to Operating Leases	The following table summarizes supplemental cash flow information related to the Company’s operating leases for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 (In thousands) Cash paid for amounts included in the measurement of lease liabilities $ 3,735 $ 3,761 Right-of-use assets obtained in exchange for new lease liabilities $ 792 $ 431
Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate	The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of March 31, 2020 and 2019: March 31, December 31, Weighted-average remaining lease term, years 6.3 6.4 Weighted-average discount rate, % 6.4 % 6.4 %

Employee Benefits and Share-B_2

Employee Benefits and Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Share-Based Compensation Expense	The following table sets forth the total share-based compensation expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 (In thousands) Cost of product and service revenues $ 1,770 $ 1,462 Research and development 1,768 1,702 Selling, general, and administrative 7,121 5,246 Total share-based compensation expense $ 10,659 $ 8,410
Assumptions Used to Value Stock Options Granted	The following assumptions were used to value stock options and Employee Stock Purchase Plan (“ESPP”) shares granted pursuant to the Company’s equity incentive plans for the three months ended March 31, 2020 and 2019: Three Months Ended March 31, 2020 2019 Stock options Expected life, years 4.7 4.5 Expected volatility, % 33.6 % 33.1 % Risk-free interest rate, % 1.4 % 2.6 % Estimated forfeiture rate, % 5.7 % 7.2 % Dividend yield, % — % — %
Assumptions Used to Value ESPP Shares Granted	Three Months Ended March 31, 2020 2019 Employee stock purchase plan shares Expected life, years 0.5 - 2.0 0.5 - 2.0 Expected volatility, % 30.4% - 39.9% 28.2% - 38.4% Risk-free interest rate, % 1.4% - 2.7% 1.3% - 2.7% Dividend yield, % — % — %
Summary of Share Option Activity	The following table summarizes the share option activity under the Company’s equity incentive plans during the three months ended March 31, 2020: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2019 3,902 $ 52.75 7.7 $ 113,198 Granted 430 85.32 Exercised (227) 36.20 Expired (2) 51.50 Forfeited (65) 64.06 Outstanding at March 31, 2020 4,038 $ 56.96 7.8 $ 57,180 Exercisable at March 31, 2020 1,586 $ 39.38 6.3 $ 42,826 Vested and expected to vest at March 31, 2020 and thereafter 3,846 $ 56.18 7.7 $ 56,526
Summary of Restricted Stock Unit Activity	Summaries of the restricted stock activity under the Company’s 2009 Equity Incentive Plan, as amended (the “2009 Plan”) are presented below for the three months ended March 31, 2020: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Restricted stock units Outstanding at December 31, 2019 544 $ 66.65 1.6 $ 44,492 Granted (Awarded) 62 85.05 Vested (Released) (33) 54.41 Forfeited (17) 66.06 Outstanding and unvested at March 31, 2020 556 $ 69.44 1.6 $ 36,482
Summary of Restricted Stock Awards Activity	Number of Weighted-Average (In thousands, except per share data) Restricted stock awards Outstanding at December 31, 2019 17 $ 81.92 Granted (Awarded) — — Vested (Released) — — Outstanding and unvested at March 31, 2020 17 $ 81.92
Summary of Performance-Based Restricted Stock Activity	A summary of the performance-based restricted stock activity under the 2009 Plan is presented below for the three months ended March 31, 2020: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2019 134 $ 55.82 Granted 63 82.41 Vested (15) 72.02 Forfeited — — Outstanding and unvested at March 31, 2020 182 $ 63.63
Ordinary Shares Reserved for Future Issuance Under Equity Incentive Plans	The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of March 31, 2020: Number of Shares (In thousands) Share options outstanding 4,038 Non-vested restricted stock awards 755 Shares authorized for future issuance 2,252 ESPP shares available for future issuance 1,322 Total shares reserved for future issuance 8,367

Organization and Summary of S_4

Organization and Summary of Significant Accounting Policies - Narrative (Details)	3 Months Ended
	Mar. 31, 2020segment
Accounting Policies [Abstract]
Number of operating segments	1
Number of reportable segments	1

Organization and Summary of S_5

Organization and Summary of Significant Accounting Policies - Summary of Allowance for Credit Losses by Asset Type (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Allowances for accounts receivable and unbilled receivables	$ 3,869	$ 3,227
Long-term unbilled receivables	33	0
Net investment in sales-type leases	$ 247	$ 225

Revenues - Narrative (Details)

Revenues - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Revenue Recognition [Abstract]
Fees to GPOs	$ 2,900	$ 2,200
Short-term deferred revenues, net	108,602		$ 90,894
Deferred cost of sales	15,400		13,100
Deferred revenues recognized	43,400
Short-term deferred revenues, gross			104,000
Long-term deferred revenues	$ 6,019		$ 7,083

Revenues - Disaggregation of Re

Revenues - Disaggregation of Revenues by Revenue Type (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue from External Customer [Line Items]
Revenues	$ 229,686	$ 202,517
Product revenues
Revenue from External Customer [Line Items]
Revenues	170,073	145,610
Hardware and software
Revenue from External Customer [Line Items]
Revenues	142,433	118,814
Consumables
Revenue from External Customer [Line Items]
Revenues	23,270	23,707
Other
Revenue from External Customer [Line Items]
Revenues	$ 4,370	$ 3,089

Revenues - Disaggregation of _2

Revenues - Disaggregation of Revenues by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue from External Customer [Line Items]
Revenues	$ 229,686	$ 202,517
United States
Revenue from External Customer [Line Items]
Revenues	207,734	180,020
Rest of world
Revenue from External Customer [Line Items]
Revenues	$ 21,952	$ 22,497

Revenues - Contract Asset and L

Revenues - Contract Asset and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Revenue Recognition [Abstract]
Short-term unbilled receivables, net	$ 10,048	$ 11,707
Long-term unbilled receivables, net	14,338	12,260
Total contract assets	24,386	23,967
Short-term deferred revenues, net	108,602	90,894
Long-term deferred revenues	6,019	7,083
Total contract liabilities	$ 114,621	$ 97,977

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Net income	$ 11,311	$ 3,284
Weighted-average shares outstanding — basic (in shares)	42,357	40,692
Effect of dilutive securities from stock award plans (in shares)	1,264	1,589
Weighted-average shares outstanding — diluted (in shares)	43,621	42,281
Net income per share - basic (in dollars per share)	$ 0.27	$ 0.08
Net income per share - diluted (in dollars per share)	$ 0.26	$ 0.08
Anti-dilutive weighted-average shares related to stock award plans (in shares)	1,744	635

Cash and Cash Equivalents and_2

Cash and Cash Equivalents and Fair Value of Financial Instruments (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 104,080,000	$ 127,210,000
Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amount			$ 100,000,000
Fixed interest rate			0.80%
Interest Rate Swap | LIBOR
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Variable rate floor			0.00%

Balance Sheet Components - Bala

Balance Sheet Components - Balance Sheet Details (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventories:
Raw materials	$ 33,945	$ 31,331
Work in process	11,957	7,620
Finished goods	66,883	69,060
Total inventories	112,785	108,011
Other long-term assets:
Capitalized software, net	90,395	85,070
Unbilled receivables, net	14,338	12,260
Deferred debt issuance costs	4,459	4,700
Other assets	1,739	1,006
Total other long-term assets	110,931	103,036
Accrued liabilities:
Operating lease liabilities, current portion	9,986	10,058
Advance payments from customers	6,442	4,006
Rebates and lease buyouts	15,156	14,911
Group purchasing organization fees	5,382	5,934
Taxes payable	5,974	3,744
Other accrued liabilities	15,120	16,914
Total accrued liabilities	$ 58,060	$ 55,567

Balance Sheet Components - Accu

Balance Sheet Components - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 845,254	$ 679,617
Other comprehensive income (loss) before reclassifications	(4,694)	769
Amounts reclassified from other comprehensive income (loss), net of tax	0	(417)
Net current-period other comprehensive income (loss), net of tax	(4,694)	352
Ending balance	878,500	730,485
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(9,446)	(10,854)
Ending balance	(14,140)	(10,502)
Foreign currency translation adjustments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(9,446)	(11,274)
Other comprehensive income (loss) before reclassifications	(4,694)	669
Amounts reclassified from other comprehensive income (loss), net of tax	0	0
Net current-period other comprehensive income (loss), net of tax	(4,694)	669
Ending balance	(14,140)	(10,605)
Unrealized gain (loss) on interest rate swap hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	0	420
Other comprehensive income (loss) before reclassifications	0	100
Amounts reclassified from other comprehensive income (loss), net of tax	0	(417)
Net current-period other comprehensive income (loss), net of tax	0	(317)
Ending balance	$ 0	$ 103

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation	$ 4.3	$ 4

Property and Equipment - Proper

Property and Equipment - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 172,714	$ 169,961
Accumulated depreciation and amortization	(119,717)	(115,715)
Total property and equipment, net	52,997	54,246
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	90,128	88,569
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	7,828	7,925
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	19,767	18,979
Software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	48,885	48,309
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 6,106	$ 6,179

Property and Equipment - Summar

Property and Equipment - Summary of Geographic Information for Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 52,997	$ 54,246
United States
Property, Plant and Equipment [Line Items]
Property and equipment, net	47,955	48,769
Rest of world
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 5,042	$ 5,477

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Goodwill Rollforward
Beginning balance	$ 336,539
Additions	0
Foreign currency exchange rate fluctuations	(1,697)
Ending balance	$ 334,842

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Intangible Assets [Line Items]
Gross carrying amount	$ 223,935	$ 224,393
Accumulated amortization	(102,487)	(98,485)
Foreign currency exchange rate fluctuations	(1,385)	(1,041)
Net carrying amount	120,063	124,867
Customer relationships
Intangible Assets [Line Items]
Gross carrying amount	134,889	135,234
Accumulated amortization	(56,727)	(54,860)
Foreign currency exchange rate fluctuations	(1,398)	(1,058)
Net carrying amount	$ 76,764	$ 79,316
Customer relationships | Minimum
Intangible Assets [Line Items]
Useful life (in years)	10 years	10 years
Customer relationships | Maximum
Intangible Assets [Line Items]
Useful life (in years)	30 years	30 years
Acquired technology
Intangible Assets [Line Items]
Gross carrying amount	$ 77,029	$ 77,142
Accumulated amortization	(38,058)	(36,194)
Foreign currency exchange rate fluctuations	4	5
Net carrying amount	$ 38,975	$ 40,953
Acquired technology | Minimum
Intangible Assets [Line Items]
Useful life (in years)	5 years	3 years
Acquired technology | Maximum
Intangible Assets [Line Items]
Useful life (in years)	20 years	20 years
Backlog
Intangible Assets [Line Items]
Gross carrying amount	$ 1,150	$ 1,150
Accumulated amortization	(863)	(791)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 287	$ 359
Useful life (in years)	4 years	4 years
Trade names
Intangible Assets [Line Items]
Gross carrying amount	$ 7,650	$ 7,650
Accumulated amortization	(5,206)	(5,037)
Foreign currency exchange rate fluctuations	9	11
Net carrying amount	$ 2,453	$ 2,624
Trade names | Minimum
Intangible Assets [Line Items]
Useful life (in years)	6 years	6 years
Trade names | Maximum
Intangible Assets [Line Items]
Useful life (in years)	12 years	12 years
Patents
Intangible Assets [Line Items]
Gross carrying amount	$ 3,217	$ 3,217
Accumulated amortization	(1,633)	(1,603)
Foreign currency exchange rate fluctuations	0	1
Net carrying amount	$ 1,584	$ 1,615
Patents | Minimum
Intangible Assets [Line Items]
Useful life (in years)	2 years	2 years
Patents | Maximum
Intangible Assets [Line Items]
Useful life (in years)	20 years	20 years

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense of intangible assets	$ 4.5	$ 4.8

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining nine months of 2020	$ 12,987
2021	16,123
2022	14,775
2023	13,679
2024	7,920
Thereafter	54,579
Net carrying amount	$ 120,063	$ 124,867

Debt and Credit Agreements - Na

Debt and Credit Agreements - Narrative (Details) - USD ($)	Nov. 15, 2019	Jan. 05, 2016	Nov. 30, 2019	Dec. 31, 2017	Mar. 31, 2020	Mar. 31, 2019	Dec. 26, 2017
Debt Instrument [Line Items]
Debt issuance costs incurred and capitalized					$ 0
Amortization of debt issuance costs					241,000	$ 573,000
Interest expense					$ 200,000	$ 1,300,000
Wells Fargo Bank
Debt Instrument [Line Items]
Debt issuance costs incurred and capitalized				$ 2,100,000
Letter of Credit | Wells Fargo Bank
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 10,000,000
Swing Line Loan | Wells Fargo Bank
Debt Instrument [Line Items]
Maximum borrowing capacity		10,000,000
Line of Credit
Debt Instrument [Line Items]
Debt issuance costs incurred and capitalized			$ 2,300,000
Line of Credit | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Minimum
Debt Instrument [Line Items]
Commitment fee rate on undrawn commitments	0.15%
Line of Credit | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Maximum
Debt Instrument [Line Items]
Commitment fee rate on undrawn commitments	0.30%
Line of Credit | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | LIBOR
Debt Instrument [Line Items]
Spread on variable interest rate	1.00%
Line of Credit | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | LIBOR | Minimum
Debt Instrument [Line Items]
Spread on variable interest rate	1.25%
Line of Credit | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | LIBOR | Maximum
Debt Instrument [Line Items]
Spread on variable interest rate	2.00%
Line of Credit | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Federal Funds
Debt Instrument [Line Items]
Spread on variable interest rate	0.50%
Line of Credit | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | LIBOR Plus 1.00% | Minimum
Debt Instrument [Line Items]
Spread on variable interest rate	0.25%
Line of Credit | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | LIBOR Plus 1.00% | Maximum
Debt Instrument [Line Items]
Spread on variable interest rate	1.00%
Line of Credit | Secured Credit Facility | Wells Fargo Bank
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 400,000,000
Line of Credit | Secured Credit Facility | Wells Fargo Bank | LIBOR | Interest Rate Option One | Minimum
Debt Instrument [Line Items]
Spread on variable interest rate		1.50%
Line of Credit | Secured Credit Facility | Wells Fargo Bank | LIBOR | Interest Rate Option One | Maximum
Debt Instrument [Line Items]
Spread on variable interest rate		2.25%
Line of Credit | Secured Credit Facility | Wells Fargo Bank | LIBOR | Interest Rate Option Two | Minimum
Debt Instrument [Line Items]
Spread on variable interest rate		0.50%
Line of Credit | Secured Credit Facility | Wells Fargo Bank | LIBOR | Interest Rate Option Two | Maximum
Debt Instrument [Line Items]
Spread on variable interest rate		1.25%
Line of Credit | Secured Credit Facility | Wells Fargo Bank | Federal Funds | Interest Rate Option Two
Debt Instrument [Line Items]
Spread on variable interest rate		0.50%
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Balance transfer	$ 80,000,000
Line of Credit | Revolving Credit Facility | Wells Fargo Bank
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 200,000,000					$ 315,000,000
Term of debt instrument		5 years
Line of Credit | Revolving Credit Facility | Wells Fargo Bank | Minimum
Debt Instrument [Line Items]
Commitment fee rate on undrawn commitments		0.20%
Line of Credit | Revolving Credit Facility | Wells Fargo Bank | Maximum
Debt Instrument [Line Items]
Commitment fee rate on undrawn commitments		0.35%
Line of Credit | Revolving Credit Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 500,000,000
Term of debt instrument	5 years
Line of Credit | Term Loan Facility
Debt Instrument [Line Items]
Balance transfer	$ (80,000,000)
Line of Credit | Term Loan Facility | Wells Fargo Bank
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 200,000,000
Term of debt instrument		5 years
Line of Credit | Letter of Credit | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity	15,000,000
Line of Credit | Swing Line Loan | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity	25,000,000
Line of Credit | Incremental Loan Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 250,000,000

Debt and Credit Agreements - Ch

Debt and Credit Agreements - Changes in the Carrying Amount of Debt Obligations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Long-term Debt [Roll Forward]
Balance	$ 50,000
Proceeds	0
Repayments	(50,000)	$ (39,000)
Balance	$ 0

Debt and Credit Agreements - _2

Debt and Credit Agreements - Changes in the Balance of Deferred Debt Issuance Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Change In Debt Issuance Costs, Net [Roll Forward]
Balance	$ 4,700
Additions	0
Amortization	(241)	$ (573)
Balance	$ 4,459

Lessor Leases - Narrative (Deta

Lessor Leases - Narrative (Details)	3 Months Ended
	Mar. 31, 2020
Lease Receivable | Customer Concentration Risk
Lessor, Lease, Description [Line Items]
Concentration risk percentage	61.00%
Minimum
Lessor, Lease, Description [Line Items]
Term of sales-type leases	1 year
Term of operating leases	1 year
Maximum
Lessor, Lease, Description [Line Items]
Term of sales-type leases	5 years
Term of operating leases	7 years

Lessor Leases - Income Recogniz

Lessor Leases - Income Recognized from Sales-Type Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Sales-type lease revenues	$ 6,392	$ 11,507
Cost of sales-type lease revenues	(2,569)	(4,820)
Selling profit on sales-type lease revenues	3,823	6,687
Interest income on sales-type lease receivables	$ 461	$ 409

Lessor Leases - Components of S

Lessor Leases - Components of Sales-Type Lease Receivables (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Net minimum lease payments to be received	$ 32,681	$ 32,360
Less: Unearned interest income portion	(2,893)	(2,840)
Net investment in sales-type leases	29,788	29,520
Less: Current portion	(9,796)	(9,770)
Long-term investment in sales-type leases, net	$ 19,992	$ 19,750

Lessor Leases - Maturity Schedu

Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Remaining nine months of 2020	$ 8,838
2021	8,048
2022	7,283
2023	5,110
2024	2,393
Thereafter	1,009
Total future minimum sales-type lease payments	32,681	$ 32,360
Present value adjustment	(2,893)	$ (2,840)
Total net investment in sales-type leases	$ 29,788

Lessor Leases - Income Recogn_2

Lessor Leases - Income Recognized from Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Rental income	$ 2,977	$ 3,287

Lessee Leases - Narrative (Deta

Lessee Leases - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Lessee, Lease, Description [Line Items]
Operating lease cost	$ 3.6	$ 3.7
Minimum
Lessee, Lease, Description [Line Items]
Term of operating leases	1 year
Maximum
Lessee, Lease, Description [Line Items]
Term of operating leases	12 years

Lessee Leases - Maturity Schedu

Lessee Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Remaining nine months of 2020	$ 10,076
2021	13,274
2022	12,157
2023	8,595
2024	8,014
Thereafter	20,100
Total operating lease payments	72,216
Present value adjustment	(13,379)
Total operating lease liabilities	58,837
Current portion of operating lease liabilities	9,986	$ 10,058
Long-term portion of operating lease liabilities	$ 48,851	$ 50,669

Lessee Leases - Supplemental Ca

Lessee Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 3,735	$ 3,761
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 792	$ 431

Lessee Leases - Weighted-Averag

Lessee Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate (Details)	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Weighted-average remaining lease term	6 years 3 months 18 days	6 years 4 months 24 days
Weighted-average discount rate	6.40%	6.40%

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Mar. 31, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
Non-cancelable purchase commitments	$ 91.7
Non-cancelable purchase commitments expected to be paid within the year	$ 90.2

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Income Tax Contingency [Line Items]
Annual effective tax rate	26.60%	23.30%
Net tax expense on sale of intellectual property rights		$ 9,600
Discrete tax benefit	$ (18)	(8,067)
Unrecognized tax benefits	17,000		$ 16,800
Accrued interest and penalties	1,100		$ 1,000
Equity Compensation
Income Tax Contingency [Line Items]
Discrete tax benefit	$ 2,800	$ 4,600

Employee Benefits and Share-B_3

Employee Benefits and Share-Based Compensation - Shared-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 10,659	$ 8,410
Cost of product and service revenues
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	1,770	1,462
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	1,768	1,702
Selling, general, and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 7,121	$ 5,246

Employee Benefits and Share-B_4

Employee Benefits and Share-Based Compensation - Assumptions Used to Value Stock Options Granted (Details) - Stock Options	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	4 years 8 months 12 days	4 years 6 months
Expected volatility, %	33.60%	33.10%
Risk-free interest rate, %	1.40%	2.60%
Estimated forfeiture rate, %	5.70%	7.20%
Dividend yield	0.00%	0.00%

Employee Benefits and Share-B_5

Employee Benefits and Share-Based Compensation - Assumptions Used to Value ESPP Shares Granted (Details) - ESPP - 1997 Plan	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility (minimum)	30.40%	28.20%
Expected volatility (maximum)	39.90%	38.40%
Risk-free interest rate (minimum)	1.40%	1.30%
Risk-free interest rate (maximum)	2.70%	2.70%
Dividend yield	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	6 months	6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	2 years	2 years

Employee Benefits and Share-B_6

Employee Benefits and Share-Based Compensation - Summary of Share Option Activity (Details) - Stock Options - 2009 Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Number of Shares
Outstanding at beginning of period (in shares)	3,902
Granted (in shares)	430
Exercised (in shares)	(227)
Expired (in shares)	(2)
Forfeited (in shares)	(65)
Outstanding at end of period (in shares)	4,038	3,902
Exercisable at end of period (in shares)	1,586
Vested and expected to vest at end of period (in shares)	3,846
Weighted-Average Exercise Price
Outstanding beginning balance (in dollars per share)	$ 52.75
Granted (in dollars per share)	85.32
Exercised (in dollars per share)	36.20
Expired (in dollars per share)	51.50
Forfeited (in dollars per share)	64.06
Outstanding ending balance (in dollars per share)	56.96	$ 52.75
Exercisable at end of period (in dollars per share)	39.38
Vested and expected to vest at end of period (in dollars per share)	$ 56.18
Weighted-Average Remaining Years
Outstanding	7 years 9 months 18 days	7 years 8 months 12 days
Exercisable	6 years 3 months 18 days
Vested and expected to vest	7 years 8 months 12 days
Aggregate Intrinsic Value
Outstanding	$ 57,180	$ 113,198
Exercisable	42,826
Vested and expected to vest	$ 56,526

Employee Benefits and Share-B_7

Employee Benefits and Share-Based Compensation - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Aug. 02, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 10,659,000	$ 8,410,000
Number of shares repurchased (in shares)	0	0
2016 and 2014 Share Repurchase Programs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining value of shares authorized for repurchase under stock repurchase programs	$ 54,900,000
The 2016 Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of shares authorized for repurchase under stock repurchase programs			$ 50,000,000
2009 Plan | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average fair value of options granted (in dollars per share)	$ 26.31	$ 24.07
Intrinsic value of options exercised	$ 9,900,000	$ 17,100,000
Unrecognized compensation cost of unvested stock options	$ 46,600,000
Weighted average period of compensation cost not yet recognized (in years)	2 years 10 months 24 days
2009 Plan | RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of compensation cost not yet recognized (in years)	3 years
Unrecognized compensation cost	$ 34,100,000
2009 Plan | RSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of compensation cost not yet recognized (in years)	1 month 6 days
Unrecognized compensation cost	$ 200,000
2009 Plan | PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of compensation cost not yet recognized (in years)	1 year 6 months
Unrecognized compensation cost	$ 6,700,000
1997 Plan | ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of compensation cost not yet recognized (in years)	1 year 4 months 24 days
Shares purchased under ESPP (in shares)	217,000	210,000
Weighted-average price of shares purchased (in dollars per share)	$ 43.51	$ 40.20
Unrecognized compensation cost	$ 7,700,000

Employee Benefits and Share-B_8

Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details) - RSUs - 2009 Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Number of Shares
Outstanding at beginning of period (in shares)	544
Granted (Awarded) (in shares)	62
Vested (Released) (in shares)	(33)
Forfeited (in shares)	(17)
Outstanding and unvested at end of period (in shares)	556	544
Weighted-Average Grant Date Fair Value
Outstanding and unvested (in dollars per share)	$ 66.65
Granted (Awarded) (in dollars per share)	85.05
Vested (Released) (in dollars per share)	54.41
Forfeited (in dollars per share)	66.06
Outstanding and unvested (in dollars per share)	$ 69.44	$ 66.65
Weighted-Average Remaining Years
Outstanding and unvested	1 year 7 months 6 days	1 year 7 months 6 days
Aggregate Intrinsic Value
Outstanding and unvested	$ 36,482	$ 44,492

Employee Benefits and Share-B_9

Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Award Activity (Details) - RSAs - 2009 Plan shares in Thousands	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Number of Shares
Outstanding at beginning of period (in shares) | shares	17
Granted (Awarded) (in shares) | shares	0
Vested (Released) (in shares) | shares	0
Outstanding and unvested at end of period (in shares) | shares	17
Weighted-Average Grant Date Fair Value
Outstanding and unvested (in dollars per share) | $ / shares	$ 81.92
Granted (Awarded) (in dollars per share) | $ / shares	0
Vested (Released) (in dollars per share) | $ / shares	0
Outstanding and unvested (in dollars per share) | $ / shares	$ 81.92

Employee Benefits and Share-_10

Employee Benefits and Share-Based Compensation - Summary of Performance-Based Restricted Stock Activity (Details) - Performance-Based Restricted Stock - 2009 Plan shares in Thousands	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Number of Shares
Outstanding at beginning of period (in shares) | shares	134
Granted (Awarded) (in shares) | shares	63
Vested (Released) (in shares) | shares	(15)
Forfeited (in shares) | shares	0
Outstanding and unvested at end of period (in shares) | shares	182
Weighted-Average Grant Date Fair Value
Outstanding and unvested (in dollars per share) | $ / shares	$ 55.82
Granted (Awarded) (in dollars per share) | $ / shares	82.41
Vested (Released) (in dollars per share) | $ / shares	72.02
Forfeited (in dollars per share) | $ / shares	0
Outstanding and unvested (in dollars per share) | $ / shares	$ 63.63

Employee Benefits and Share-_11

Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details) shares in Thousands	Mar. 31, 2020shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	8,367
Share options outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	4,038
Non-vested restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	755
Shares authorized for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	2,252
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	1,322

Equity Offerings - Narrative (D

Equity Offerings - Narrative (Details) - Distribution Agreement - USD ($) $ / shares in Units, shares in Thousands	Nov. 03, 2017	Mar. 31, 2019	Mar. 31, 2020
Subsidiary, Sale of Stock [Line Items]
Maximum aggregate offering price	$ 125,000,000
Gross proceeds from sales of common stock		$ 20,600,000
Issuance costs on sales of common stock		$ 400,000
Number of shares sold (in shares)		243
Price per share sold (in dollars per share)		$ 84.98
Aggregate value of shares available to be offered			$ 31,500,000

Restructuring Expenses - Narrat

Restructuring Expenses - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)
Restructuring and Related Activities [Abstract]
Restructuring expenses	$ 3.5
Unpaid balance related to restructuring plan	$ 1.7

Uncategorized Items - omcl-2020

Label	Element	Value
Accounting Standards Update 2016-13 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (264,000)
Accounting Standards Update 2016-13 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (264,000)